Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS

被引:102
作者
Villar, LM
Masjuan, J
González-Porqué, P
Plaza, J
Sádaba, MC
Roldán, E
Bootello, A
Alvarez-Cermeño, JC
机构
[1] Hosp Ramon & Cajal, Serv Immunol, Dept Immunol, Madrid 28034, Spain
[2] Hosp Ramon & Cajal, Dept Neurol, Madrid 28034, Spain
[3] Univ Alcala de Henares, Dept Med, Alcala De Henares, Spain
关键词
D O I
10.1212/WNL.59.4.555
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The authors have recently described that intrathecal IgM synthesis (ITMS) correlates with a higher disability in patients with clinically definite MS (CDMS). Objective: To follow-up a group of patients with MS in the initial stages of the disease to evaluate if the presence of ITMS correlates with a worse evolution. Methods: Oligoclonal IgM bands were performed in 22 patients with MS with a mean of 1.14 months of evolution. Patients were followed for a period ranging from 6 to 36 months (mean, 21.4 months). During follow-up, time to conversion to CDMS, number of relapses, and changes in Expanded Disability Status Scale (EDSS) score were evaluated. Results: Patients were divided into two groups according to the presence (Group 1, 10 patients) or absence (Group 2, 12 patients) of ITMS. No clinical differences were observed between the groups at inclusion in the study. During the follow-up, the probability of conversion to CDMS was greater in Group 1 (90% of the patients had converted to CDMS after 8 months of follow-up) than in Group 2 (51% of patients had converted to CDMS after 36 months of follow-up) (p = 0.0001). Patients from Group 1 had more relapses (mean, 2.0) than those from Group 2 (mean, 0.58) (p = 0.02). At the end of the study, patients from Group 1 had higher EDSS scores (mean, 1.70) than those from Group 2 (mean, 0.79) (p = 0.02). Conclusion: The presence of oligoclonal IgM bands in CSF can be a prognostic marker in the early phases of MS.
引用
收藏
页码:555 / 559
页数:5
相关论文
共 26 条
[1]  
Agius MA, 1999, ACTA NEUROL SCAND, V100, P139
[2]   INDIRECT EVIDENCE FOR NITRIC-OXIDE INVOLVEMENT IN MULTIPLE-SCLEROSIS BY CHARACTERIZATION OF CIRCULATING ANTIBODIES DIRECTED AGAINST CONJUGATED S-NITROSOCYSTEINE [J].
BOULLERNE, AI ;
PETRY, KG ;
MEYNARD, M ;
GEFFARD, M .
JOURNAL OF NEUROIMMUNOLOGY, 1995, 60 (1-2) :117-124
[3]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[4]   Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].
Ebers, GC ;
Rice, G ;
Lesaux, J ;
Paty, D ;
Oger, J ;
Li, DKB ;
Beall, S ;
Devonshire, V ;
Hashimoto, S ;
Hooge, J ;
Kastrukoff, L ;
Krieger, C ;
Mezei, M ;
Seland, P ;
Vorobeychi, G ;
Morrison, W ;
Nelson, J ;
Freedman, MS ;
Chrisie, S ;
Nelson, R ;
Rabinovitch, H ;
Freedman, C ;
Hartung, HP ;
Rieckmann, P ;
Archelos, J ;
Jung, S ;
Weilbach, F ;
Flachenecke, P ;
Sauer, J ;
Hommes, O ;
Jongen, P ;
Brouwer, S ;
McLeod, J ;
Pollard, J ;
Ng, R ;
Sandberg-Wollheim, M ;
Källén, K ;
Nilsson, P ;
Ekberg, R ;
Lundgren, A ;
Jadbäck, G ;
Wikström, J ;
Multanen, J ;
Valjakka, M ;
Carton, H ;
Lissoir, F ;
Declerq, I ;
Vieren, M ;
Peeters, E ;
Dubois, B .
LANCET, 1998, 352 (9139) :1498-1504
[5]   CSF MYELIN BASIC-PROTEIN, IGG AND IGM LEVELS IN 101 MS PATIENTS BEFORE AND AFTER TREATMENT WITH HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE [J].
FREQUIN, STFM ;
BARKHOF, F ;
LAMERS, KJB ;
HOMMES, OR ;
BORM, GF .
ACTA NEUROLOGICA SCANDINAVICA, 1992, 86 (03) :291-297
[6]   The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis - Identification and characterization of the primary demyelinating lesion [J].
Gay, FW ;
Drye, TJ ;
Dick, GWA ;
Esiri, MM .
BRAIN, 1997, 120 :1461-1483
[7]   Identification of autoantibodies associated with myelin damage in multiple sclerosis [J].
Genain, CP ;
Cannella, B ;
Hauser, SL ;
Raine, CS .
NATURE MEDICINE, 1999, 5 (02) :170-175
[8]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[9]   INTRATHECAL SYNTHESIS OF IGM AND IGA IN NEUROLOGICAL DISEASES - COMPARISON OF 2 FORMULAS WITH ISOELECTRIC-FOCUSING [J].
KAISER, R ;
LUCKING, CH .
CLINICA CHIMICA ACTA, 1993, 216 (1-2) :39-51
[10]   ISOELECTRIC-FOCUSING OF CEREBROSPINAL-FLUID IMMUNOGLOBULIN-G - AN ANNOTATED UPDATE [J].
KEIR, G ;
LUXTON, RW ;
THOMPSON, EJ .
ANNALS OF CLINICAL BIOCHEMISTRY, 1990, 27 :436-443